 |
|
|
|||||
Noom's new weight-loss program formalizes what many have been experimenting with and hyping on Reddit and TikTok: microdosing GLP-1 drugs. The digital healthcare company has launched a Microdose GLP-1Rx Program priced at USD 119 to start, followed by USD 199 monthly, which includes both medication and a "GLP-1 Companion" behavior change platform. Noom's protocol uses doses that are 25% or less of standard maintenance doses, with 70% of members reporting no side effects while still achieving significant weight loss.The approach tackles three barriers to addressing obesity through Ozempic and its brethren: medication cost, side effects and sustainable behavior change. By personalizing dosing schedules to each member rather than following a one-size-fits-all approach, Noom aims to maximize outcomes while minimizing the digestive issues that lead many to abandon GLP-1 treatments. This strategy bridges the gap between DIY experimentation and conventional medical protocols, potentially making these medications accessible to those deterred by both high costs and unpleasant side effects.TREND BITEWhile early adopters chased dramatic transformations through high-dose protocols, mainstream consumers now gravitate toward gentler interventions. Microdosing is a sign of the "Ozempic era" maturing, with preferences shifting from dramatic transformations to sustainable lifestyle integration; think less "Biggest Loser" and more "Couch to 5K." With Noom repackaging GLP-1 medication as an accessible health tool for the masses, the drugs' impact on the food industry is likely to increase. (See "Ozempic Is Costing Grocery Stores Billions" and "Ozempic Is Shrinking Appetites. Restaurants Are Shrinking the Food.")
Category:
Marketing and Advertising
Catch up on select AI news and developments from the past week or so. Stay in the know. Read the full article at MarketingProfs
Category:
Marketing and Advertising
Unveiled this week, Fourier's GR-3 robot described as its first "care-centric humanoid" stands apart from the clinical, industrial automatons dominating the market with its distinctly human-like expressions and emotional intelligence. The compact robot features an animated LED face capable of displaying a range of emotions, from happiness to concern, responding dynamically to human interactions. Unlike robots designed primarily for task efficiency, GR-3 prioritizes emotional connection through its rounded, approachable design, soft-touch materials and interfaces that emphasize accessibility over technical complexity.In healthcare settings, GR-3 could serve as a companion for elderly patients that doesn't just bring them their meds at the correct time, but ensures they take them, with a friendly nudge and maybe a bit of banter. Educational institutions are exploring GR-3's potential for supporting children with learning differences, where its non-threatening presence and endless patience create a judgment-free learning environment. And corporate environments might deploy the robots in customer service roles where a soft touch is as valuable as conveying information.TREND BITEThe emergence of emotionally intelligent machines like GR-3 signals a shift in consumer expectations. As automation becomes ubiquitous, the competitive edge won't lie in functionality alone, but in how tech makes people feel. For businesses, this means reconsidering design philosophies across products and services. We're moving beyond the era of sterile efficiency toward technology that acknowledges our need for warmth, personality and genuine connection.
Category:
Marketing and Advertising
All news |
||||||||||||||||||
|
||||||||||||||||||